Abstract: The present disclosure relates to systems and methods for generating an occlusion region in an image. The system includes a plurality of imaging devices, a storage device and at least one processor in communication with the storage device, wherein each of the plurality of imaging devices is configured to capture a component image presenting a scene, When executing the instructions, the at least one processor is configured to cause the system to determine a first occlusion region in an image formed based on at least one component image. The at least one processor is configured to determine how to generate a second occlusion region in at least one of the plurality of component images based on the area of the first occlusion region and an area threshold.

Abstract: Migrating a logical partition with a native logical port including establishing in the target computing system a target VIOS that includes a virtual network interface controller (vNIC) server, the vNIC server of the target VIOS coupled for data communications to a first target virtual adapter; copying the logical partition including a vNIC client to the target computing system; starting the logical partition; establishing, by the vNIC client of the logical partition, data communications with the vNIC server of the target VIOS, including performing I/O data communications between the logical partition and the first target virtual adapter; establishing a second logical port in the logical partition on the target computing system, including coupling for I/O data communications the second logical port to a second target virtual adapter; and performing I/O data communications from the logical partition to the second target virtual adapter through the second logical port.

Abstract: Migrating a logical partition with a native logical port including establishing in the target computing system a target VIOS that includes a virtual network interface controller (vNIC) server, the vNIC server of the target VIOS coupled for data communications to a first target virtual adapter; copying the logical partition including a vNIC client to the target computing system; starting the logical partition; establishing, by the vNIC client of the logical partition, data communications with the vNIC server of the target VIOS, including performing I/O data communications between the logical partition and the first target virtual adapter; establishing a second logical port in the logical partition on the target computing system, including coupling for I/O data communications the second logical port to a second target virtual adapter; and performing I/O data communications from the logical partition to the second target virtual adapter through the second logical port.

Abstract: The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.

Abstract: The present disclosure relates to devices and methods for detecting and removing vapor for an imaging acquisition device. A device for detecting and removing vapor may include a first light guide. The first light guide may include a first end to receive a light beam, and a second end to output the light beam at a predetermined angle with respect to a reference plane, so that when the light beam enters a target light transmission media from the first light guide, the light beam substantially perfectly reflects between a first surface and a second surface of the target light transmission media. The first surface and second surface may substantially parallel to the reference plane.

Abstract: The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.

Abstract: The present disclosure relates to high-throughput detection of polyketides using genetically encoded biosensors.

Abstract: The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.

Abstract: Migrating a logical partition with a native logical port including establishing in the target computing system a target VIOS that includes a virtual network interface controller (vNIC) server, the vNIC server of the target VIOS coupled for data communications to a first target virtual adapter; copying the logical partition including a vNIC client to the target computing system; starting the logical partition; establishing, by the vNIC client of the logical partition, data communications with the vNIC server of the target VIOS, including performing I/O data communications between the logical partition and the first target virtual adapter; establishing a second logical port in the logical partition on the target computing system, including coupling for I/O data communications the second logical port to a second target virtual adapter; and performing I/O data communications from the logical partition to the second target virtual adapter through the second logical port.

Abstract: A method for determining and managing computing resources within a virtualized computing environment in response to restarting a set of partitions. The method includes at least one computer processor identifying a set of partitions affected by an event within a first computing system, the set of affected partitions is identified for restart. The method further includes creating a set of temporary partitions within a network accessible second computing system that correspond the affected set of partitions of the first computing system. The method further includes determining one or more sets of computing resources, of the second computing system, corresponding to the created temporary partitions. The method further includes deleting the set of temporary partitions. The method further includes provisioning a set of partitions within the second computing system based, at least in part, on the determined one or more sets of computing resources corresponding to the affected set of partitions.

Abstract: A stick-trap type trap for tobacco pests includes a bottom plate, a face plate, a glue for sticking pests and a lure containing tobacco pest pheromones. The bottom plate is engaged with the face plate. A trapping cavity is formed between the bottom plate and the face plate. A side surface of the trapping cavity is communicated with an internal environment. The glue is coated on an internal surface of the bottom plate opposite to the face surface. The lure is located on the internal surface of the bottom plate. The face plate is made of materials as follows: (A) transparent materials or magnifying lens materials with the function of increasing visual angle; (B) non-transparent sheet materials, wherein an observation hole is provided on the face plate, a transparent dust-proof board is inserted into the observation hole for observing an amount of trapped pests.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function.

Abstract: A method for treating a human comprises administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

Abstract: A method for storing tobacco, including: 1) constructing a sealed plastic tent system for a tobacco stack capable of mechanically controlling internal storage conditions in a tobacco warehouse; and 2) performing fumigation, dehumidification, and/or a combination thereof for the tobacco stack.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.

Abstract: In one embodiment, a data structure stores information about the number of client virtual I/O adapters, the number of possible destination VIOS hosts and the number of available slots on those hosts. The information is used to iteratively assign adapters to available slots of the VIOS hosts of the destination server to which a client partition is to be migrated. A method comprises testing the data structure to determine whether conditions exist that make allocation of the adapter to a VIOS host unquestionable.

Abstract: The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function.

Abstract: The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.